

Press Release

Eurocor presented 12 months outcome of Spanish Registry at EuroPCR in Paris

Bengaluru, India | Paris, France | May 19, 2011

- During the Symposium (Drug-eluting balloons: Current practice and future perspectives), the 12 month Follow-Up results of the Spanish Multicenter Registry were presented by the Principal Investigator Dr. Antonio Serra.
- International Symposium dedicated to experiences with drug-eluting balloons (DEB).

Eurocor GmbH, a wholly-owned subsidiary of Opto Circuits (India) Ltd., announced the 12 months outcome of the Spanish Multicenter Registry at EuroPCR in Paris during the international Eurocor Symposium. 250 patients were enrolled in 10 Spanish centers. The study was conducted to investigate the outcome after DIOR® drug-eluting balloon (DEB) was used for the treatment of in-stent restenosis (ISR) lesions. The investigations included ISR due to bare metal stents (BMS) as well as ISR due to drug-eluting stents (DES). A second focus of that study was the treatment of small vessels, a challenging subset of patients, where treatment options are currently limited. The results at 12 months follow-up show a low target lesion revascularization (TLR) rate of 9.2% in BMS-ISR and 14.8% in DES-ISR. In very small vessels (1.98 mm mean vessel diameter) the TLR rate at 12 months was very low with 2.9%, which is remarkable. This shows that the treatment of coronary in-stent restenosis with the paclitaxel-eluting balloon DIOR® provides good immediate and midterm outcomes. The manuscript on the subset of patients with ISR lesions has been accepted for publication recently. The results were presented by Dr. Antonio Serra (Spain).

During the well-visited symposium, Prof. Silber (Germany) provided a lecture on the current role of DEBs. He pointed out that the DIOR DEB is in accordance with the ESC guidelines (2010) Ila, which recommends that DEB can be used for ISR in BMS. Dr. Pieter Stella (Netherlands) then presented the database of the Valentines Trial with the largest group of patients ever enrolled to show efficacy of DEB in treatment of ISR. The studies show that the DIOR® (DEB) is safe and effective in ISR.

Prof. Schulte from Germany highlighted a glimpse of first experiences with the drug-eluting peripheral PTA Balloon FREEWAY™ and announced the first results of a new randomized study. Dr. Chandra from India, Dr. Alfredo Rodriguez from Argentina and Prof. Huay Cheem Tan from Singapore rounded the international view on innovative DEB technologies and experiences with high class products such as DIOR® DEB and FREEWAY™ DEB.

About: Eurocor GmbH

Eurocor GmbH is a rapidly growing European Life Sciences Technology corporation specialising in the research, development and manufacture of interventional cardiology products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular devices.

The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimisation of clinically effective technologies. For more information, please visit www.eurocor.de.

Follow us at http://twitter.com/Eurocor_Germany

About: Opto Circuits (India) Limited

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCUI

Website: www.optocircuits.com

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Ormed](#), [Mediaid](#) and [Unetixs](#). The company's key markets are North America, Europe and BRIC countries.

| Contact | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Opto Circuits (India) Ltd. E: Media - media@optoindia.com ; Investors - ir@optoindia.com T: +91 80 2852 8088 | Adfactors PR Neha Goenka E: neha.goenka@adfactorspr.com T: +91 22 2281 3565 |